Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes
暂无分享,去创建一个
Johan Lindberg | Kamila Czene | Mattias Rantalainen | Juni Palmgren | Per Hall | Henrik Grönberg | Jonas Bergh | Johan Hartman | Daniel Klevebring | J. Palmgren | Jingmei Li | K. Czene | K. Humphreys | J. Lindberg | H. Grönberg | M. Rantalainen | J. Bergh | J. Hartman | L. Lindström | N. Tobin | J. Frisell | J. Holm | S. Törnberg | Sven Törnberg | Jingmei Li | Keith Humphreys | E. Ivansson | Jan Frisell | Gabriela Prochazka | Emma Ivansson | Nicholas P Tobin | Linda Sofie Lindström | Johanna Holm | Camilla Cristando | Camilla Cristando | Gabriela Prochazka | P. Hall | Daniel Klevebring
[1] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Christer Larsson,et al. Correction: Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer. , 2016, Cancer research.
[3] H. Friess,et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein , 1997, Oncogene.
[4] L. Tabár,et al. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. , 1987, British Journal of Cancer.
[5] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[6] B. Rush,et al. Interval breast cancer: a more aggressive subset of breast neoplasias. , 1983, Surgery.
[7] Maria Sala,et al. Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain , 2010, Cancer Causes & Control.
[8] P. Porter,et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. , 1999, Journal of the National Cancer Institute.
[9] Yali Dou,et al. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases , 2015, Nature Reviews Cancer.
[10] T. Urano,et al. PPP1R3 gene (protein phosphatase 1) alterations in colorectal cancer and its relationship to metastasis. , 2005, Oncology reports.
[11] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[12] G. Svane,et al. Breast Cancer Screening Program in Stockholm County, Sweden – Aspects of Organization and Quality Assurance , 2010, Breast Care.
[13] Jingmei Li,et al. Risk factors and tumor characteristics of interval cancers by mammographic density. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[15] S. Mook,et al. Independent prognostic value of screen detection in invasive breast cancer. , 2011, Journal of the National Cancer Institute.
[16] A. Ashworth,et al. Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? , 2009, Genes, chromosomes & cancer.
[17] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[18] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[19] P. Hall,et al. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] P. Hall,et al. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] Jingmei Li,et al. High-throughput mammographic-density measurement: a tool for risk prediction of breast cancer , 2012, Breast Cancer Research.
[23] Aleix Prat Aparicio. Comprehensive molecular portraits of human breast tumours , 2012 .
[24] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[25] D. Rayson,et al. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. , 2011, Clinical breast cancer.
[26] X. Castells,et al. Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[27] J. Machiels,et al. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer , 2014, Breast Cancer Research.
[28] J. Palazzo,et al. IMP3, a Proposed Novel Basal Phenotype Marker, is Commonly Overexpressed in Adenoid Cystic Carcinomas but not in Apocrine Carcinomas of the Breast , 2011, Applied immunohistochemistry & molecular morphology : AIMM.
[29] Yu Shen,et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. , 2005, Journal of the National Cancer Institute.
[30] Charles M. Perou,et al. Triple-Negative Breast Cancer: Risk Factors to Potential Targets , 2008, Clinical Cancer Research.
[31] M. Ringnér,et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics , 2010, Breast Cancer Research.
[32] S. Dhanasekaran,et al. Targeting the MLL complex in castration resistant prostate cancer , 2015, Nature Medicine.
[33] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[34] K. Czene,et al. Abstract P6-06-17: Gene signature model predicts metastatic onset better than standard clinical markers – Nested case-control design uniquely enables enrichment for biologically relevant features , 2013 .